Eli Lilly says its monoclonal antibody prevented Covid-19 infections in clinical trial
Eli Lilly said Thursday that its monoclonal antibody prevented Covid-19 infections in nursing home residents and staff in a clinical trial, the first time such a treatment has been shown to prevent infection.
Lilly released the results in a press release, although it said that it would publish the data in a research paper as quickly as possible.
